Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

NCT05305989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Graft-versus-host-disease

Interventions

DRUG: Belumosudil 200 mg QD
DRUG: Belumosudil 200 mg BID
DRUG: Belumosudil 400 mg QD

Sponsor

Kadmon, a Sanofi Company